Evolution des thérapies anti-cancéreuses systémiques.

PONCIN, Aurélie; Jerusalem, Guy

Request a copy

Article (Scientific journals)

Evolution des thérapies anti-cancéreuses systémiques.

PONCIN, Aurélie; Jerusalem, Guy

2020 • In Revue Médicale de Liège, 75 (5-6), p. 466-472

Peer reviewed

Permalink
https://hdl.handle.net/2268/252364

PubMed
32496699

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Evolution of systemic anti-cancer therapies.pdf

Publisher postprint (530.72 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Humans; Immunotherapy; Neoplasms/drug therapy; Chemotherapy; Targeted therapy; Cancer; oncology

Abstract :

[en] Before the advent of chemotherapy in the 1940s, cancer treatment was dominated by surgery and radiation therapy. The developments of targeted anti-cancer therapies in the 2000s followed by immunotherapy have largely changed the treatment landscape in particular in the metastatic setting. Here we provide a history of these advances.

Disciplines :

Oncology

Author, co-author :

PONCIN, Aurélie ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'oncologie médicale

Jerusalem, Guy ; Université de Liège - ULiège > Département des sciences cliniques > Oncologie

Language :

French

Title :

Evolution des thérapies anti-cancéreuses systémiques.

Alternative titles :

[en] Evolution of systemic anti-cancer therapies

Publication date :

2020

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

5-6

Pages :

466-472

Peer reviewed :

Peer reviewed

Available on ORBi :

since 10 November 2020

Statistics

Number of views

126 (5 by ULiège)

Number of downloads

4 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
Hanahan D, Weinberg RA. Hallmarks of cancer : The next generation. Cell 2011;144:646-74.
Soria JC, Vignot S, Massard C, et al. Cours de chimiothérapie antitumorale et traitement médical du cancer, XXVIIIe cours de Gustave-Roussy. Le book 2013;12-6.
Dickens E, Ahmed S. Principles of cancer treatment by chemotherapy. Surgery 2018;36:134-38.
Morrison WB. Cancer chemotherapy : An annotated history. J Vet Intern Med 2010;24:1249-62.
DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res 2008;68:8643-53.
Frénel JS, Campone M. Chimiothérapie des cancers du sein non métastatiques : état des lieux en 2010. J Gynécol Obst Biol Reprod 2010;39:79-84.
Bria E, Nistico C, Cuppone F, et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer : pooled analysis of 15, 500 patients. Cancer 2006;106:2337-44.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling : A patientlevel meta-Analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet 2019;393:144-52.
Hafraoui K, Humblet-Baron S, Baron F, et al. Comment je traite. la leucémie myéloïde chronique. Rev Med Liege 2003;58:7-12.
Druker BJ, Lydon NB. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000;105:3-7.
O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years : The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Onco 2010;11:1029-35.
Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008;53:245-66.
Gerber DE. Targeted therapies : A new generation of cancer treatments. Am Fam Physician 2008;77:311-9.
Kalyn R. Overview of targeted therapies in Oncology. J Oncol Pharm Pract 2007;13:199-205.
Torti D, Trusolino L. Oncogene addiction as a foundational rationale for targeted anti-cancer therapy : promises and perils. EMBO Mol Med 2011;3:623-36.
Bickels J, Kollender Y, Merinsky O, et al. Coley's toxin : historical perspective. Isr Med Assoc J 2002;4:471-2.
Muenst S, Läubli H, Soysal SD, et al. The immune system and cancer evasion strategies: Therapeutic concepts. J Intern Med 2016;279:541-62.
Mittal D, Gubin MM, Schreiber RD, et al. New insights into cancer immunoediting and its three component phases elimination, equilibrium and escape. Curr Opin Immunol 2014;27:16-25.
Greenberg PD, Riddell SR. Tumor-specific T-cell immunity: ready for prime time? J Natl Cancer Inst 1992;84:105961.
Passarelli A, Mannavola F, Stucci LS, et al. Immune system and melanoma biology : A balance between immunosurveillance and immune escape. Oncotarget 2017;8:106132-42.
Pennock GK, Chow LQM. The evolving role of immune checkpoint inhibitors in cancer treatment. Oncologist 2015;20:812-22.
Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015;348:56-61.
Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-9.
Hirsch L, Zitvogel L, Eggermont A, et al. PD-Loma : A cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade. Br J Cancer 2019;120:3-5.
Chen DS, Mellman I. Oncology meets immunology : The cancer-immunity cycle. Immunity 2013;39:1-10
Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017;377:1919-29.
Gellrich FF, Schmitz M, Beissert S, et al. Anti-PD-1 and novel combinations in the treatment of melanoma. An update. J Clin Med 2020;9:piiE223.
Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012;12:237-51.
Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018;378:2078-92.